G-2788

2025-10-19 18:42

Written by ARCIMS 26 ARCIMS 26 in Sunday 2025-10-19 18:42

Synergistic Effects of Bavachinin in Combination with Either Ezetimibe or Atorvastatin on Liver Biomarkers: A Randomized Controlled Trial in hyperlipidemic rats with NAFLD

 Seyed AmirHadi Hosseini 1, Yazdan Naderi 2, Seyed Alireza Mirilavasani 3, Frits van Osch 4, Frits van Osch 5, Rasoul Samimi 6, Hossein Piri 7 ©, Fatemeh eftekhari 8 ℗, Fatemeh eftekhari 9   

 MSc student, Student Research Committee, School of Medicine, Qazvin University of Medical Sciences, Qazvin, Iran

 2Department of Pharmacology, School of Medicine, Qazvin University of Medical Sciences, Qazvin, Iran

 3MSc student, Health Food Innovation Management, Maastricht University, Campus Venlo, Venlo, The Netherlands

 Department of Clinical Epidemiology, VieCuri Medical Centre, Venlo, the Netherlands

 Department of Epidemiology, NUTRIM School for Nutrition and Metabolism, Maastricht University, Maastricht, the Netherlands.

 Medical Microbiology Research Center, Qazvin University of Medical Sciences, Qazvin, Iran

Associate Professor, Cellular and Molecular Research Centre, Research Institute for Prevention of Non-Communicable Disease, Qazvin University of Medical Sciences, Qazvin, Iran

 Student research committee, Qazvin University of Medical Sciences, Qazvin, Iran

 USERN Office ,Qazvin University of Medical Sciences,Qazvin,Iran

Email: f.e.lab.btk1997@gmail.com
 

Abstract

Synergistic Effects of Bavachinin in Combination with Either Ezetimibe or Atorvastatin on Liver Biomarkers: A Randomized Controlled Trial in hyperlipidemic rats with NAFLD Introduction: Non-alcoholic fatty liver disease (NAFLD) is a common multisystem disorder, identified as the main cause of chronic liver disease globally. Despite extensive studies, not any FDA-approved medication affects NAFLD in a specific manner. bavachinin, a flavonoid taken from Psoralea corylifolia with a pan-agonistic effect on PPAR nuclear receptors (NRs), exhibiting antioxidant properties. This study has a goal to assess the separate and mixed effects of bavachinin in either ezetimibe or atorvastatin on liver biomarkers. Methods and Materials: Thirty-five male rats were randomly divided into seven groups: bavachinin, atorvastatin, ezetimibe, atorvastatin combined with bavachinin, ezetimibe combined with bavachinin, hyperlipidemic control, and normal control. Hyperlipidemia injected in all groups for ten weeks other than the normal control through diet. Then, the mice in each group received their required drug (atorvastatin, bavachinin, ezetimibe, and a mix of bavachinin and ezetimibe, and bavachinin and atorvastatin) for four weeks. Finally, serum samples were collected from the tail vein before and after treatment to measure Interleukin-10 (IL-10), Aspartame Transaminase (AST), Alanine Transaminase (ALT), and Alkaline Phosphatase (ALP) levels. Liver samples were subjected to Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining. Results: Wilcoxon sign-ranked test showed significant improvements in AST in all five intervention groups after treatment. Significant improvements in ALT were observed in the bavachinin and mixed ezetimibe plus bavachinin groups. In addition, significant improvements in IL-10 were noted in the ezetimibe, bavachinin, and bavachinin mixed with either ezetimibe or atorvastatin treatments. ALP showed no significant differences before and after the intervention. Kruskal-Wallis ANOVA showed significant improvements in ALT, AST, and IL-10 in all groups. Post-hoc Mann-Whitney U-test showed that the mixed treatment of both drugs with bavachinin led to a significant improvement in AST compared to the hyperlipidemic control, and mixed ezetimibe plus bavachinin showed a significant reduction in ALT compared to the hyperlipidemic control. In addition, mixed atorvastatin plus bavachinin showed a significant increase in IL-10 compared to the bavachinin group although mixed ezetimibe plus bavachinin demonstrated a significant increase in IL-10 compared to the bavachinin group. Histological analysis also disclosed that bavachinin itself had a hepatoprotective effect which reduces apoptosis compared to the hyperlipidemic group. Conclusion and Discussion: The findings of this study showed that bavachinin left a hopeful message so as to prevent liver disease progress in patients with metabolic syndrome. Nevertheless, concerns in certain cases pertaining to the side effects of estrogen-like Psoralea corylifolia were observed. This shows the need for further research.


Keywords: bavachinin, hepatic biomarkers, NAFLD, inflammation, novel drugs


 

Feedback

What is your opinion? Click on the stars you want.

Comments (0)

No Comment yet. Be the first!

Post a comment